Chemotherapy Induced Peripheral Neuropathy (CIPN) Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market 1
Chemotherapy Induced Peripheral Neuropathy (CIPN) Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
Chemotherapy Induced Peripheral Neuropathy (CIPN) Market:
DelveInsight’s “Chemotherapy Induced Peripheral Neuropathy (CIPN) – Market Analysis Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Chemotherapy Induced Peripheral Neuropathy (CIPN) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

DelveInsight’s “Chemotherapy Induced Peripheral Neuropathy (CIPN) – Market Analysis Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Chemotherapy Induced Peripheral Neuropathy (CIPN) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. 

Some of the key facts of the Chemotherapy Induced Peripheral Neuropathy (CIPN)  Market Report:

  • Japan accounts for approximately ~19% of the total incident cases of CIPN in 7MM and in 2021, the incident population of chemotherapy-induced peripheral neuropathy in Japan was found to be ~307,800 cases.
  • In terms of severity, the majority of the patients were diagnosed with moderate severity. This was followed by mild severity and the least number was observed for severe cases. In 2021, incident cases of mild, moderate, and severe CIPN in Japan were found to be ~ 89,300; ~157,000; and  ~61,600 cases respectively
  • In 2021, amongst breast cancer, lung cancer, colorectal cancer, pancreatic cancer, and multiple myeloma, the highest incident population of CIPN in Japan was observed in colorectal cancer patients with  ~71,800 cases. 

Key Benefits of the Chemotherapy-Induced Peripheral Neuropathy (CIPN)  Report:

  • The Chemotherapy Induced Peripheral Neuropathy (CIPN) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Chemotherapy Induced Peripheral Neuropathy (CIPN) Epidemiology Report and Model provide an overview of the global trends of Chemotherapy Induced Peripheral Neuropathy (CIPN) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Chemotherapy Induced Peripheral Neuropathy (CIPN) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM for the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Chemotherapy Induced Peripheral Neuropathy (CIPN)
  • The report provides the segmentation of the Chemotherapy Induced Peripheral Neuropathy (CIPN) epidemiology

 

Got queries? Click here to learn more about the Chemotherapy Induced Peripheral Neuropathy (CIPN)  Market Landscape

Chemotherapy-Induced Peripheral Neuropathy (CIPN)  Overview

Cancer is a major cause of mortality worldwide and the number of deaths due to cancer is on the rise. In less than the last 20 years, cancer has emerged as the leading cause of mortality. And the number of cancer survivors is expected to increase in the coming years due to the increasing emergence of sensitive tests for detecting cancer and the administration of frontline chemotherapeutic agents. Chemotherapeutics are effective in arresting the progression of cancer because they are often designed to differentially target and eliminate rapidly dividing cancer cells.

Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, dose-dependent complication of anticancer drugs, including platinum, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib. It not only leads to dose reduction or discontinuation of treatment but also decreases the quality of life of cancer survivors. CIPN occurs in ~20% of patients given standard doses of chemotherapy and in almost 100% of patients treated with high doses.

Primary afferent neurons and their cell bodies located in the DRG are particularly vulnerable to the toxic effects of chemotherapy because they do not have a protective blood-brain barrier that is present in the CNS. Without the blood-brain barrier, substances in the blood can freely exchange across the walls of DRG and affect primary afferents. In cancer patients, this produces an array of sensory disturbances (e.g., numbness, tingling, burning, or dysesthesias) broadly known as CIPN that affects the hands and feet in a glove and stocking distribution. Patients typically present with symptoms consistent with CIPN weeks or months after beginning chemotherapy treatment. 

 

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Epidemiological Insights:

 

  • With increasing cancer survivorship, the long-term disease burden of CIPN is gaining more attention. CIPN is one of the most common complications of chemotherapy. CIPN can produce excruciating pain and make it difficult to perform routine activities. After treatment, CIPN might linger for weeks, months, or even years. It can lead to more serious problems, such as changes in the heart rate and blood pressure, deadly falls, difficulty breathing, paralysis, or organ failure if it develops badly enough. 
  • The total incident population of chemotherapy-induced peripheral neuropathy (CIPN) in the 7MM countries was ~1,598,000 in 2021
  • In 2021, the incident population of CIPN in the US for breast cancer was ~67% (91,000 cases) of the total CIPN cases in the US including lung, colorectal, pancreatic, and multiple myeloma cancer.

Chemotherapy Induced Peripheral Neuropathy (CIPN) Epidemiological Segmentation 

  • Total Chemotherapy Induced Peripheral Neuropathy (CIPN) incident population
  • Total Chemotherapy Induced Peripheral Neuropathy (CIPN) severity-specific incident population 
  • Total Chemotherapy Induced Peripheral Neuropathy (CIPN) incident population by cancer type 
  • Total Chemotherapy Induced Peripheral Neuropathy (CIPN) incident population by chemotherapic agents 

Chemotherapy-Induced Peripheral Neuropathy (CIPN)   Market Outlook 

The Chemotherapy-Induced Peripheral Neuropathy (CIPN) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

 

This segment gives a thorough detail of the market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

The market size of Chemotherapy Induced Peripheral Neuropathy (CIPN) in the G8 Countries is expected to increase at a CAGR of 2.94% for the study period (2016-2027). The expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of CIPN. Among the different classes of therapies that are currently prescribed to patients with CIPN, opioid analgesics is the most prescribed one that led to the highest market size among other classes. China accounts for the highest market size of CIPN in comparison to the United States, the EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.

 

Learn more by requesting for sample @ Chemotherapy Induced Peripheral Neuropathy (CIPN)  Market Trends

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Key Companies

  • Apexian Pharmaceuticals Inc, 
  • Aphios Corp, 
  • Asahi Kasei Pharma Corp, 
  • Bristol-Myers Squibb Co, 
  • Regulonix LLC, 
  • Winsantor Inc, 
  • Abalone Bio Inc, 
  • Achelios Therapeutics Inc, 
  • Algenis, 
  •  Algo Therapeutix SAS
  • And many others 

 

Chemotherapy Induced Peripheral Neuropathy (CIPN) Therapies

 

  •  Cannabinoid Receptor 2
  •  Cannabinoid Receptor 1, 
  •  Glutamate Ionotropic Receptor 
  •  NMDA Type Subunit, 
  •  Histone Deacetylase 6, 
  • Sodium Channel Protein Type 9 Subunit Alpha,
  •  DNA (Apurinic or Apyrimidinic Site) 
  • Lyase, Free Radical, 
  • Muscarinic Acetylcholine Receptor M1, 
  • Prostaglandin G/H Synthase 1
  • And many more 

 

Table of Contents

 

  1. Key Insights 
  2. Report Introduction 
  3. Executive Summary of Chemotherapy-Induced Peripheral Neuropathy (CIPN)    
  4. Disease Background and Overview
  5. Epidemiology and patient population
  6. Chemotherapy-Induced Peripheral Neuropathy (CIPN)  Emerging Therapies
  7. Chemotherapy-Induced Peripheral Neuropathy (CIPN)  Market Outlook
  8. Market Access and Reimbursement of Therapies
  9. Appendix
  10. Chemotherapy-Induced Peripheral Neuropathy (CIPN)  Report Methodology
  11. DelveInsight Capabilities
  12. Disclaimer
  13. About DelveInsight

Click here to read more about  Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Insight

Related Reports

Chemotherapy Induced Peripheral Neuropathy (CIPN)  Pipeline Insight, 2022

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Leave a Reply

Your email address will not be published. Required fields are marked *